Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07 2020 - 7:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that the
Company will present at the 38th annual J.P. Morgan Healthcare
Conference, to be held at the Westin St. Francis in San Francisco.
Tony J. Hunt, Repligen’s president and chief executive officer, is
scheduled to present a company overview on Wednesday, January 15,
2020 at 11:30 a.m. PT. A live audio webcast of the presentation
will be accessible through the Investor Events section of the
Company’s website at www.repligen.com. A recorded replay will be
available approximately one hour after the conclusion of the live
event, and will be accessible for up to 90 days following the
event.
About Repligen CorporationRepligen
Corporation is a global life sciences company that develops and
commercializes highly innovative bioprocessing technologies and
systems that increase efficiencies in the process of manufacturing
biological drugs. We are inspiring advances in bioprocessing for
the customers we serve; primarily biopharmaceutical drug developers
and contract development and manufacturing organizations (CDMOs)
worldwide. Our corporate headquarters are located in Waltham, MA
(USA), and we have additional administrative and manufacturing
operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez,
CA; Lund, Sweden; Breda, The Netherlands and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024